Allina Health, Virginia Piper Cancer Institute

Minneapolis, Minnesota 55407

0 studies enrolling now · 11 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Estrogen Receptor Positive HER2- Breast Cancer, Advanced Non Small Cell Lung Cancer, Advanced Solid Tumors, Bladder Cancer, Breast Cancer, Carcinoma, Non-small-cell Lung, Colorectal Cancer, Colorectal Cancer Metastatic, Esophageal Neoplasms, Head and Neck Cancer, Hepatocellular Carcinoma

Studies at this site

• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer — Completed
• Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia — Completed
• Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) — Completed
• A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer — Completed
• Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors — Running, not enrolling
• Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer — Completed
• Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers — Completed
• A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors — Completed
• A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer — Completed
• Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC — Completed
• GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer — Stopped early